Pharmaceuticals & Biotech Swedish Community

In 2026, the story is no longer about how many companies Swedencare can buy, but how effectively it can scale its existing brands (ProDen PlaqueOff and NaturVet) into global Big Box retail and e-commerce The Pet Humanization Play Swedencare's narrative rests on three pillars: The Global Brand Portfolio: Moving from a single product company to a diversified pet health giant. The story is about cross-selling, taking a successful dental product from Sweden and putting it in 2,000 Walmart stores in the US The Channel Pivot: Swedencare is taking direct control of its destiny by moving Amazon sales inhouse and entering Big Box retail like Walmart, CVS etc.Read more

Oncolytics Biotech is pushing a new immune-based cancer treatment that’s showing encouraging early signs in some of the hardest-to-treat cancers, including pancreatic and certain digestive cancers. A recent green light from a German regulator and fresh conference results hint at momentum, but the big question is whether later trial readouts can hold up.Read more

Catalysts Most Immediate Catalyst (1–2 Years): Strong Oncology Portfolio Growth: AstraZeneca’s cancer drugs Tagrisso, Imfinzi, Enhertu, and Calquence continue gaining market share, driving double-digit revenue growth in oncology. Respiratory & Cardiovascular Expansion: New approvals and label expansions in Farxiga (diabetes/heart failure) and Tezspire (severe asthma) can drive meaningful sales upside.Read more

Biovica is trying to turn its cancer blood test into a go-to tool in early breast cancer care, helped by new trial results and deals that could widen access in the US and Europe. The big question is whether these partnerships and approvals arrive fast enough, because the company may need more funding and recent sales momentum has cooled.Read more

Key Takeaways Rapid commercial adoption and efficient operations position Oncopeptides for strong revenue and margin growth, surpassing typical biotech peers. Strategic partnerships, industry trends, and a differentiated product platform create opportunities for immediate cash flow strength and long-term valuation upside.Read more

Cinclus Pharma is betting on a next-generation treatment for severe heartburn that could benefit from rising diagnoses and growing interest in this new type of medicine worldwide. But with most of the story riding on one late-stage drug and progress depending on trial results, partners, and pricing pressure, the path to a successful launch is far from certain.Read more

Moberg Pharma is trying to turn a Europe-first rollout into real growth, with new market approvals and a clearer path to sell its key treatment across more countries. The catch is that setbacks in the US and ended partnerships could slow progress, making the next steps in supply, approvals, and launch timing crucial.Read more

BioGaia is pushing beyond its baby-focused probiotics by ramping up adult health products and landing more space in big U.S. retailers, aiming to ride the shift toward everyday “preventative” wellness. The catch is it’s spending heavily on marketing and expansion while cash flow and profits are under pressure, so the key question is whether today’s investment turns into stronger growth and a broader product mix.Read more

Swedish Orphan Biovitrum is pushing several newer medicines into more countries and new uses, with early uptake suggesting it could win share in some key markets. The big question is whether approvals and launches stay on track while competition, pricing pressure, and cross-border policy changes don’t derail growth.Read more